Dr. Hodges brings 25 years of biopharmaceutical development experience in both large pharmaceutical and biotechnology companies. Prior to joining Amplyx, Dr. Hodges served as chief medical officer and head of drug development for Santaris Pharma A/S, an RNA therapeutic company developing drugs for infectious diseases, oncology and orphan diseases (Santaris was acquired by Hoffmann-La Roche AG). Dr. Hodges joined Santaris from Pfizer Inc., where he was the development team leader for Vfend, the gold-standard therapy for invasive aspergillosis; he also worked on the Eraxis and Diflucan antifungal programs and was involved in the development of a number of antiviral and antibacterial programs including Zithromax. Dr. Hodges practiced medicine at several University of London hospitals and received board certification in internal medicine. He earned his medical degree at the Westminster Medical School, University of London, and his undergraduate degree in pharmacology from Kings College, University of London. He currently serves on the scientific advisory boards of Arcturus Therapeutics and Exicure Therapeutics. Dr. Hodges brings 25 years of biopharmaceutical development experience in both large pharmaceutical and biotechnology companies. Prior to joining Amplyx, Dr. Hodges served as chief medical officer and head of drug development for Santaris Pharma A/S, an RNA therapeutic company developing drugs for infectious diseases, oncology and orphan diseases (Santaris was acquired by Hoffmann-La Roche AG). Dr. Hodges joined Santaris from Pfizer Inc., where he was the development team leader for Vfend, the gold-standard therapy for invasive aspergillosis; he also worked on the Eraxis and Diflucan antifungal programs and was involved in the development of a number of antiviral and antibacterial programs including Zithromax. Dr. Hodges practiced medicine at several University of London hospitals and received board certification in internal medicine. He earned his medical degree at the Westminster Medical School, University of London, and his undergraduate degree in pharmacology from Kings College, University of London. He currently serves on the scientific advisory boards of Arcturus Therapeutics and Exicure Therapeutics.

Business